We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Information on COVID-19, including guidance on the assessment and management of suspected UK cases.
Information on how UK companies can control risks when doing business in Thailand.
Information on how UK companies can control risks when doing business in Brazil.
If you’re travelling abroad, it's important to take out appropriate travel insurance before you go.
Information for pregnant women with singleton (having only one baby) and twin pregnancies who have received a higher-chance result from the combined or quadruple screening test
Data sources of numbers relating to the coronavirus pandemic in the UK.
How we assess issues of potential regulatory concern
The MHRA will introduce a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects
Guidance for living safely with respiratory infections, including coronavirus (COVID-19).
FCDO travel advice for Panama. Includes safety and security, insurance, entry requirements and legal differences.
Data on the real-world efficacy of the COVID-19 vaccines.
How the MHRA makes decisions on when a product is a medical device (borderline products), and which risk class should apply to a medical device.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
This guidance provides information on important security and political risks which UK businesses may face when operating in Japan.
Guidance and advice from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
Find out how you could do the SFI actions for soils.
Guidance for industry on flexible approaches to regulation we are taking during the COVID-19 outbreak.
This guidance provides information on COVID-19 in homelessness, domestic abuse refuge, respite room and asylum seeker accommodation settings.
How to use a case-control study to evaluate your digital health product.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.